The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma

Oncology
Nicola SilvestrisGiuseppe Colucci

Abstract

Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development.

Citations

Nov 21, 2014·Pharmacogenomics·Nicola SilvestrisDaniele Santini
Sep 28, 2012·Journal of Cancer Research and Clinical Oncology·Isabelle MessnerKarl-Ludwig Schaefer
Feb 9, 2013·Biochimica Et Biophysica Acta·Natalia ElfimovaMargarete Odenthal
Jun 25, 2014·Expert Review of Gastroenterology & Hepatology·Christian RolfoMarc Peeters
May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Afshin DerakhshaniBehzad Baradaran

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.